Clinical trials: Active Population
Inflammation, Rheumatoid Arthritis
Efficacy of NNC0142-0002 in Subjects With Rheumatoid Arthritis (RA)
This trial is conducted in Europe. The aim of this trial is to evaluate the clinical efficacy of a single dose of NNC0142-0002 administered to subjects with active rheumatoid arthritis (RA).
- Trial name
- NCT01181050
- Testing
- NNC0142-0002
- Where
- 3 sites in Germany, Russia and 1 more
- Volunteers
- 63 people
- Sponsor
- Janssen Research & Development, LLC
RA
To Evaluate Sarilumab - SAR153191 (REGN88) - Auto-injector Device In Patients With Rheumatoid Arthritis
Primary Objective: To collect real-use data of the sarilumab auto-injector device (AID) used by rheumatoid arthritis (RA) participants.
- Trial name
- SARIL-RA-EASY (NCT02057250)
- Testing
- Sarilumab, Auto-Injector Device (AID), Pre-filled Syringe (PFS)
- Where
- 53 sites in United States, Chile and 4 more
- Volunteers
- 217 people
- Sponsor
- Sanofi
Crohn Disease
Efficacy, Safety and Pharmacokinetics of BI 655066/ABBV-066 (Risankizumab) in Patients With Active, Moderate-to-severe Crohn's Disease.
This study is a proof of concept, multi-center, randomized, double-blind, placebo-controlled, parallel-group phase 2 dose-ranging study of BI 655066/ABBV-066 (risankizumab), an IL-23 p19 antagonist monoclonal antibody, in…
- Trial name
- NCT02031276
- Testing
- risankizumab IV, risankizumab SC
- Volunteers
- 121 people
- Sponsor
- AbbVie
Venous Thromboembolism
Dabigatran Etexilate Compared With Enoxaparin in Prevention of Venous Thromboembolism (VTE) Following Total Hip Arthroplasty
The primary objective of the trial is to demonstrate non-inferiority of 220 mg oral dabigatran etexilate compared to 40 mg subcutaneous enoxaparin administered once daily.
- Trial name
- NCT00657150
- Testing
- Enoxaparin, Dabigatran etexilate
- Where
- 108 sites in United States, Australia and 17 more
- Volunteers
- 2,055 people
- Sponsor
- Boehringer Ingelheim
Chronic Kidney Disease, Dialysis
Long-term Extension Study of MCI-196
The Primary Objectives of this study are to assess the long-term efficacy of treatment with colestilan (MCI-196) (including combination therapy) and to assess the long-term safety of treatment with colestilan (MCI-196) (including…
- Conditions
- Chronic Kidney Disease, Dialysis, Hyperphosphatemia, Paediatric
- Trial name
- NCT01814917
- Testing
- colestilan, CBPB
- Where
- United Kingdom
- Volunteers
- 6 people
- Sponsor
- Tanabe Pharma Corporation
Type 2 Diabetes Mellitus
A 24-week Open-Label, Phase 3b Trial With a 28-week Extension to Evaluate the Efficacy and Safety of Saxagliptin Co-administered With Dapagliflozin Compared to Insulin Glargine in Subjects withType 2 Diabetes Who Have Glycemic Control on Metformin
This research study of subjects with inadequately controlled type 2 diabetes mellitus (T2DM) will compare the glycemic control (measured by HbA1c) in subjects co-administered saxagliptin and dapagliflozin, in addition to…
- Trial name
- NCT02551874
- Testing
- Saxagliptin, Onglyza, Dapagliflozin, Farxiga, Glargine insulin
- Where
- 40 sites in United States, Czechia and 8 more
- Volunteers
- 650 people
- Sponsor
- AstraZeneca
Asthma (Diagnosis)
Beclometasone Dipropionate and Formoterol Inhalation Aerosol for Asthma
A multicenter, randomized, double-blind, active-controlled, parallel-group Phase III clinical study comparing the efficacy and safety of Beclometasone Dipropionate and Formoterol Inhalation Aerosol versus FOSTER® in patients with…
- Trial name
- NCT07768891
- Testing
- Beclometasone Dipropionate and Formoterol Inhalation Aerosol, FOSTER®
- Where
- China
- Volunteers
- 416 people
- Sponsor
- Lunan Better Pharmaceutical Co., LTD.
Psoriatic Arthritis
VTX958 Versus Placebo for the Treatment of Active Psoriatic Arthritis (Tranquility-PsA)
The objective of this study is to evaluate if VTX958 is safe and effective in adult participants with active Psoriatic Arthritis.
- Trial name
- NCT05715125
- Testing
- Dose A VTX958, Dose B VTX958
- Where
- 46 sites in United States, Bulgaria and 5 more
- Volunteers
- 205 people
- Sponsor
- Ventyx Biosciences, Inc
Arthritis, Rheumatoid
Oral Baricitinib (LY3009104)Treatment in Japanese Participants With Active Rheumatoid Arthritis on Background Methotrexate Therapy
This is a Phase 2b, outpatient, randomized, double-blinded (with a single-blind extension), placebo-controlled, dose-ranging, parallel-group study of baricitinib (LY3009104) in Japanese participants with active rheumatoid…
- Trial name
- NCT01469013
- Testing
- Baricitinib, Methotrexate
- Where
- 14 sites in Japan
- Volunteers
- 145 people
- Sponsor
- Eli Lilly and Company
Rheumatoid Arthritis
A Study to Evaluate the Effects of Rituximab on Immune Responses in Subjects With Active Rheumatoid Arthritis Receiving Background Methotrexate
This was a Phase II, randomized, open-label, multicenter study designed to evaluate the immune response to vaccines after administration of 1000 mg of rituximab in subjects with active rheumatoid arthritis (RA) who were receiving…
- Trial name
- SIERRA (NCT00282308)
- Testing
- Rituximab, Methotrexate, Methylprednisone
- Where
- 34 sites in United States
- Volunteers
- 103 people
- Sponsor
- Genentech, Inc.
Primary Dyslipidemia, Mixed Dyslipidemia
Prevail-Us: A Study Of Pitavastatin 4 mg Vs. Pravastatin 40 mg In Patients With Primary Hyperlipidemia Or Mixed Dyslipidemia
Randomized, double-blind, double-dummy, 12-week, active-controlled study of pitavastatin 4 mg daily(QD) vs. pravastatin 40 mg daily(QD) in subjects with primary hyperlipidemia or mixed dyslipidemia.
- Trial name
- PREVAIL-US (NCT01256476)
- Testing
- pitavastatin, pravastatin
- Where
- 44 sites in United States
- Volunteers
- 328 people
- Sponsor
- Kowa Research Institute, Inc.
Crohn's Disease
A Study of the Efficacy and Safety of Guselkumab in Participants With Moderately to Severely Active Crohn's Disease
The purpose of this study is to evaluate the clinical efficacy (GALAXI 1), clinical and endoscopic efficacy (GALAXI 2 and GALAXI 3) and safety of guselkumab in participants with Crohn's disease.
- Trial name
- GALAXI (NCT03466411)
- Testing
- Guselkumab Dose 1, Guselkumab Dose 2, Guselkumab Dose 3
- Where
- 579 sites in United States, Australia and 41 more
- Volunteers
- 1,409 people
- Sponsor
- Janssen Research & Development, LLC
Pneumococcal Infections
A Phase I Clinical Trial of a 13-valent Pneumococcal Conjugate Vaccine and 14-valent Pneumococcal Conjugate Vaccine in Adults
The purpose of this study is to evaluate the safety and immunogenicity of LBVE013 (Pneumococcal 13-valent conjugate vaccine [diphtheria CRM197 protein]) or LBVE014 (Pneumococcal 14-valent conjugate vaccine [diphtheria CRM197…
- Trial name
- NCT02892812
- Testing
- Pneumococcal conjugate vaccine
- Where
- South Korea
- Volunteers
- 63 people, healthy volunteers welcome
- Sponsor
- LG Life Sciences
Adenocarcinoma of Lung
To Compare Efficacy and Safety of CT-P16 and European Union-Approved Avastin as First-Line Treatment for Metastatic or Recurrent Non-Squamous Non-Small Cell Lung Cancer
To demonstrate that CT-P16 is similar to EU-Approved Avastin in terms of efficacy as determined by objective response rate (ORR) during the Induction Study Period
- Trial name
- NCT03676192
- Testing
- CT-P16, Avastin
- Where
- South Korea
- Volunteers
- 689 people
- Sponsor
- Celltrion
Arthritis, Rheumatoid
A Study Comparing LBAL to Humira® in Subjects With Active Rheumatoid Arthritis Despite Methotrexate Therapy
This is a randomized, double-blind, parallel group, multicenter clinical study to evaluate the efficacy, safety, pharmacokinetics and immunogenicity of LBAL compared to Humira® in subjects with active Rheumatoid Arthritis despite…
- Trial name
- NCT02746380
- Testing
- LBAL, Humira®
- Where
- 2 sites in Japan, South Korea
- Volunteers
- 383 people
- Sponsor
- LG Life Sciences
Sickle Cell Disease
Study of a Single Dose of a 21-valent Pneumococcal Conjugate Vaccine in Children and Adolescents With Sickle Cell Disease
The purpose of this study is to measure whether PCV21 vaccine (investigational pneumococcal vaccine) is safe and can help the body to develop germ-fighting agents called "antibodies" (immunogenicity) compared with 20vPCV…
- Trial name
- NCT07247188
- Testing
- PCV21, 20vPCV
- Where
- 7 sites in United States, Dominican Republic
- Volunteers
- 100 people
- Sponsor
- Sanofi
Rheumatoid Arthritis
Comparative Study of BAT1806 to RoActemra® in Rheumatoid Arthritis Patients With Inadequate Response to Methotrexate
This is a Phase 3, multicenter, multinational, randomized, double-blind, parallel-group, active-control study to compare efficacy, safety, immunogenicity, and PK of BAT1806 compared with RoActemra in subjects with RA that is…
- Trial name
- NCT03830203
- Testing
- BAT1806, Actemra(EU-licensed)
- Where
- China
- Volunteers
- 621 people
- Sponsor
- Bio-Thera Solutions
Osteoporosis, Postmenopausal
Comparative Efficacy, Safety, PK, and Immunogenicity Study
this comparative clinical study is designed to demonstrate that LY06006 and EU-Prolia have no clinically meaningful differences in clinical efficacy, pharmacodynamic (PD), safety, PK, and immunogenicity in postmenopausal women…
- Trial name
- NCT05853354
- Testing
- Denosumab
- Where
- 39 sites in United States, Bulgaria and 3 more
- Volunteers
- 392 people
- Sponsor
- Luye Pharma Group Ltd.
Restless Legs Syndrome
Simulated Driving Study in Restless Legs Syndrome
This study was a multi center, randomized, double blind, active and placebo controlled, parallel group study to assess simulated driving performance in XP13512 treated subjects with Restless Legs Syndrome (RLS).
- Trial name
- XP083 (NCT01332318)
- Testing
- XP13512, Diphenhydramine
- Where
- United States
- Volunteers
- 130 people
- Sponsor
- XenoPort, Inc.
Bronchial Asthma
Efficacy and Tolerability of Beclomethasone Plus Salbutamol in HFA pMDI Fixed Combination vs Beclomethasone Plus Salbutamol in CFC pMDI Fixed Combination in a 12-week Treatment Period of Adult Patients With Uncontrolled Asthma
The purpose of this trial is to verify if the test treatment BDP 250 mcg/salbutamol 100 mcg HFA pMDI fixed combination is non-inferior to BDP 250 mcg/salbutamol 100 mcg pMDI fixed combination given with the conventional CFC…
- Trial name
- NCT00528723
- Testing
- salbutamol 100 mcg, BDP/salbutamol HFA pMDI, BDP/salbutamol CFC pMDI
- Where
- 25 sites in Italy, Russia and 2 more
- Volunteers
- 180 people
- Sponsor
- Chiesi Farmaceutici S.p.A.
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.